Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Indaptus Therapeutics Inc INDP

Healthcare Biotechnology
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be... see more

Recent & Breaking News (NDAQ:INDP)

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

GlobeNewswire 8 days ago

Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference

GlobeNewswire March 28, 2024

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

GlobeNewswire March 25, 2024

Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024

GlobeNewswire March 18, 2024

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 13, 2024

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

GlobeNewswire March 4, 2024

Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire February 15, 2024

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

GlobeNewswire February 8, 2024

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

GlobeNewswire January 4, 2024

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2023

Indaptus Therapeutics' Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study

GlobeNewswire November 6, 2023

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

GlobeNewswire October 31, 2023

Indaptus Therapeutics to Present at the LD Micro Main Event XVI

GlobeNewswire September 27, 2023

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

GlobeNewswire September 26, 2023

Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

GlobeNewswire September 19, 2023

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2023

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

GlobeNewswire August 10, 2023

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

GlobeNewswire August 7, 2023

Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference

GlobeNewswire June 15, 2023